A Phase 2 Multicenter, Open Label, Single Arm Study Evaluating the Effect of ALLN-177 to Reduce Urinary Oxalate Excretion in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

Trial Profile

A Phase 2 Multicenter, Open Label, Single Arm Study Evaluating the Effect of ALLN-177 to Reduce Urinary Oxalate Excretion in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs ALLN 177 (Primary)
  • Indications Hyperoxaluria; Renal calculi
  • Focus Therapeutic Use
  • Sponsors Allena Pharmaceuticals
  • Most Recent Events

    • 12 Nov 2015 According to an Allena Pharmaceuticals media release, based on the positive results of this trial the company has initiated additional phase II trials (see profiles 254853 and 254852).
    • 12 Nov 2015 Primary endpoint (Change in 24 hour urinary oxalate excretion) has been met, as reported in an Allena Pharmaceuticals media release.
    • 12 Nov 2015 According to an Allena Pharmaceuticals media release, results from this trial, were presented at the American Society of Nephrology (ASN) Kidney Week 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top